➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
Express Scripts
Colorcon
Merck

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,178,554


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,178,554 protect, and when does it expire?

Patent 8,178,554 protects AVYCAZ and is included in one NDA.

This patent has fifty-eight patent family members in forty-two countries.

Summary for Patent: 8,178,554
Title:Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: ##STR00001## The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
Inventor(s): Lampilas; Maxime (Romainville, FR), Aszodi; Jozsef (Tucson, AZ), Rowlands; David Alan (Poissy, FR), Fromentin; Claude (Paris, FR)
Assignee:
Application Number:13/068,399
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,178,554

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Free Forever Trial
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM ⤷  Free Forever Trial
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,178,554

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 10121Aug 1, 2000

International Family Members for US Patent 8,178,554

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1614 ⤷  Free Forever Trial
Argentina 031716 ⤷  Free Forever Trial
Austria 263768 ⤷  Free Forever Trial
Australia 2001279905 ⤷  Free Forever Trial
Australia 7990501 ⤷  Free Forever Trial
Bulgaria 107497 ⤷  Free Forever Trial
Bulgaria 66094 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKesson
Express Scripts
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.